Xbrane Biopharma AB/News/Change of number of shares and votes in Xbrane

Change of number of shares and votes in Xbrane

31 October 2022 - 08:00

Xbrane Biopharma AB (“Xbrane” or the “Company”) has according to previously announced information resolved to carry out a directed share issue of in total 2,361,112 shares. The share issue has resulted in a change of the registered share capital and shares and votes in Xbrane.

As of 31 October 2022, the total number of shares and votes in the Company amounts to 27,506,018. The Company's registered share capital amounts to approximately SEK 6,166,466.

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference products. The lead candidate Ximluci® is under registration in Europe with a planned launch during the first quarter 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Provided by: MFN

Xbrane Biopharma AB

Xbrane Biopharma develops and manufactures biosimilars and generic long-acting injectables. It offers products including Spherotide, for the treatment of prostate cancer, breast cancer, endometriosis, and myoma and Xlucane, a ranibizumab biosimilar for the treatment of age-related macular degeneration, diabetes-related macular edema, diabetic retinopathy, and retinal vein occlusion....

Learn more about company

Related news

23.03.2023

ExpreS2ion Biotech Holding AB

Bulletin from ExpreS2ion's extraordinary general meeting on 23 March 2023

Helsingborg, Sweden, 23 March 2023 – ExpreS2ion Biotech Holding AB's (“ExpreS2ion” or the “Company”) extraordinary general meeting took place today. The extraordinary general meeting resolved to approve the Board of Directors' resolution to carry out a new issue of units consisting of shares and war...

23.03.2023

Alzinova AB

BioStock: Alzinovas patentansökan stärker portföljen

Alzinova har lämnat in en ny patentansökan för en vidareutvecklad form av den monoklonala antikroppen ALZ-201. Enligt bolagets vd Kristina Torfgård är patentstrategin och ansökan viktiga delar i bolagets strävan att positionera Alzinova som en ledande aktör f...

23.03.2023

Fluicell AB

Fluicell nylanserar och uppgraderar Dynaflow® Resolve mot större marknader

Fluicell AB (publ) (”Fluicell” eller ”Bolaget”) meddelar idag att Bolaget nylanserar produkten Dynaflow® Resolve. Dynaflow® Resolve är Fluicells plattform för jonkanalsscreening som har varit en del av Bolagets produktportfölj sedan 2017 och används av läkemedels- och biotechbolag världen över för f...

23.03.2023

2cureX AB

2cureX announces launch of updated Specimen Collection Set

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today the launch of an updated Specimen Collection Set. The improvements provide, compared to the previous one, an enhanced preservation of living tumoral cells, a smaller footprin...